Lauren Sciences
Lauren Sciences is dedicated to solving the major medical challenge in treating central nervous system (CNS) diseases by enabling therapeutic agents to cross the blood-brain barrier (BBB). Their breakthrough V-Smart® Platform allows non-invasive, triple-targeted CNS delivery of non-BBB penetrant therapeutic agents, including nucleic acids, antibodies, biologics, and small molecules. The company’s pipeline includes V-Smart® Nanomedicines in development for various CNS indications such as ALS, Parkinson’s Disease, Alzheimer’s Disease, Neuro-HIV, Glioblastoma, and Chronic Pain. They collaborate with pharmaceutical companies to develop proprietary therapeutic agents, aiming to significantly improve patient outcomes by enabling treatments currently unavailable due to BBB, PK, bioavailability, toxicity, or invasiveness.
Industries
Nr. of Employees
small (1-50)
Lauren Sciences
345 East 94 Street, New York, NY 10128
Patents
Products
CNS-targeted nanocarrier platform
A non-invasive, multi-targeted nanocarrier platform designed to facilitate transport of therapeutics across the blood–brain barrier to enable treatment of CNS diseases.
CNS-targeted nanomedicines (development pipeline)
Pipeline of nanomedicine candidates under development for multiple CNS indications, including neurodegenerative diseases and CNS oncology.
CNS-targeted nanocarrier platform
A non-invasive, multi-targeted nanocarrier platform designed to facilitate transport of therapeutics across the blood–brain barrier to enable treatment of CNS diseases.
CNS-targeted nanomedicines (development pipeline)
Pipeline of nanomedicine candidates under development for multiple CNS indications, including neurodegenerative diseases and CNS oncology.
Services
Collaborative development services to formulate and advance nanomedicine candidates that incorporate partners' proprietary therapeutic agents for CNS indications under confidentiality arrangements.
Collaborative development services to formulate and advance nanomedicine candidates that incorporate partners' proprietary therapeutic agents for CNS indications under confidentiality arrangements.
Expertise Areas
- Targeted CNS drug delivery
- Nanomedicine formulation and development
- Lipid chemistry and polymer/supramolecular chemistry for drug delivery
- Preclinical neuroscience research
Key Technologies
- Nanocarrier-based CNS delivery
- Lipid-based nanocarriers
- Polymer-based nanocarriers
- Microencapsulation
News & Updates
Lauren Sciences received multiple grants from NIH-NIMH, FightMND, The ALS Association, Voices Against Brain Cancer, Dana’s Angels Research Trust, The Campbell Foundation for AIDS, and The Michael J. Fox Foundation for Parkinson’s, supporting their development of V-Smart® Nanomedicines.
Lauren Sciences licensed V-Smart® technology from Ben Gurion University, Israel, which received early research support from various foundations and organizations including the US-Israel Binational Science Foundation, Israel Chief Scientist’s Office, Johnson & Johnson, and the Israel Science Foundation.
Lauren Sciences received multiple grants from NIH-NIMH, FightMND, The ALS Association, Voices Against Brain Cancer, Dana’s Angels Research Trust, The Campbell Foundation for AIDS, and The Michael J. Fox Foundation for Parkinson’s, supporting their development of V-Smart® Nanomedicines.
Lauren Sciences licensed V-Smart® technology from Ben Gurion University, Israel, which received early research support from various foundations and organizations including the US-Israel Binational Science Foundation, Israel Chief Scientist’s Office, Johnson & Johnson, and the Israel Science Foundation.